Market Access Letter

Breakthrough Lost Its Medicare Edge

Since October 1, 2026, Breakthrough Device designation has stopped being a general exemption from the substantial clinical improvement test for Medicare add-on payment and outpatient pass-through. Only devices inside the transition rules keep it. CMS made that change in the FY 2027 hospital inpatient final rule (CMS-1849-F, 91 FR 49570), and it is in force. The coverage route CMS has offered alongside it, RAPID, is still a proposal. A 2027 plan has to carry those two facts on separate timelines.

The payment change works in two settings. For inpatient new technology add-on payments (NTAP), CMS repealed the Breakthrough alternative pathway starting with FY 2028 applications, so an applicant must now show substantial clinical improvement. For pass-through in the outpatient system, any application CMS receives from October 1, 2026 onward faces the same requirement. The repealed route had carried most recent approvals. CMS approved 19 technologies for FY 2027 add-on payments, and 16 of them came through alternative pathways, a count that includes antimicrobial products.

Most of the detail sits in the transition. On the inpatient side, a device designated by September 30, 2026 keeps the alternative pathway for FY 2028 and FY 2029, provided FDA authorization for the designated use comes by May 1, 2028. On the outpatient side, a device designated by September 30, 2026 and authorized as a Breakthrough device for that indication stays eligible under the alternative pathway through calendar year (CY) 2029. Pass-through applications on file by September 30 for authorized Breakthrough devices are judged under the old pathway. Designation on October 1 or later carries neither protection.

The two protections differ in a way that is easy to miss. Only the inpatient one names an authorization deadline. In the outpatient section, the preamble and the amended text of 42 CFR 419.66 also state the end point differently. Before a forecast books pass-through revenue on the strength of the outpatient exception, I would have the team read the regulation text itself and record which wording it relied on.

Coverage runs on its own clock. On August 11, 2026, CMS published a notice with comment period describing the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway (91 FR 51710). The comment period ended October 13, and as of October 31 no final notice had appeared in the Federal Register. Under the proposal, CMS would publish its draft coverage decision, a national coverage determination (NCD) in proposed form, when FDA authorizes the device. A final NCD would follow in roughly 60 days for Class II and 90 days for Class III.

Eligibility, as written, is tight. RAPID admits Breakthrough devices in two groups: Class III devices headed for premarket approval (PMA), and Class II devices headed for De Novo that are enrolled in FDA's Total Product Life Cycle Advisory Program (TAP). A sponsor has to enter before its investigational device exemption (IDE) presubmission. CMS describes devices that are already on the market, or already in an IDE study, as "not appropriate" for the pathway.

The RAPID notice also closed the Transitional Coverage for Emerging Technologies (TCET) pathway to new entrants for now. CMS's NCD dashboard (labeled "Updated: September 2026", retrieved October 31) shows no pending TCET topics and 11 requests on the NCD wait list. A sponsor already past IDE presubmission is left with today's routes: a conventional NCD request, which CMS says generally takes 9 to 12 months, or local coverage through its Medicare Administrative Contractor (MAC).

Two documents have not issued. CMS has set no date for a final RAPID notice. The CY 2027 OPPS/ASC final rule (CMS-1850) was not in the Federal Register or on public inspection as of October 31; its last confirmed status was pending review at the Office of Information and Regulatory Affairs (OIRA) on October 30. In its July proposal, CMS said that rule will decide 13 complete pass-through applications, 10 filed under the alternative pathway and 3 under the traditional one. Until it publishes, none of those 13 belongs in a forecast as decided.

The designation date now sorts programs into two groups. A program designated by September 30 has a payment route with a deadline attached, and the planning task is to protect the FDA timeline against May 1, 2028 and to model a slip. A program designated later will need substantial clinical improvement data for any new add-on payment or pass-through application. I would write the endpoints that support that claim into the pivotal protocol now, while the protocol can still change. Hospital finance teams should treat new-technology payment for those later devices as a device-by-device question. Anyone valuing a device program should hold coverage timing and payment eligibility as two risks with separate dates.

Tina Ivovic
UnifiMed


Statuses as of October 31, 2026. Sources: FY 2027 IPPS/LTCH PPS final rule (FR Doc 2026-15833, August 4, 2026) and correction (FR Doc 2026-19946); RAPID notice with comment period (FR Doc 2026-16368, August 11, 2026); CY 2027 OPPS/ASC proposed rule (FR Doc 2026-13656, July 7, 2026); CMS NCD dashboard. General information; not legal, billing or coding advice.